Tiny Biotech Just Beat AbbVie's Drug: Risk for Investors?
A tiny biotech just beat AbbVie's blockbuster in early-stage results, prompting fresh questions about the durability ...
This introductory paragraph highlights how yearly drawdown data for index funds reveals cyclic risk patterns and guides more resilient investment choices.
25,260 articlesA tiny biotech just beat AbbVie's blockbuster in early-stage results, prompting fresh questions about the durability ...
AMD and Intel report mixed Q1 2026 results as AI data-center demand surges. AMD-led momentum in data center contrasts...
When private materials move from a safe shelf to a digital vault, money and privacy collide. This article examines hu...
A major trading move shows Clearline Capital expanding its Core Scientific holding just as Bitcoin mining evolves int...
Behind every AI breakthrough lies a power backstop. This article explains how Vertiv quietly powering every AI data c...
MIAX is shaping 2026 in a dynamic way, and the first-quarter earnings transcript offers clues about growth drivers an...
Cannabis stocks remain volatile and Canopy Growth sits at a crossroads in 2026. This article explains why many invest...
Intuitive Machines announced an $800 million acquisition that pivots the company from lunar landers to a full space p...
As Joby Aviation gears up for commercial flights in 2026, investors are weighing a bold ramp in production, regulator...
A looming legal clash could redefine how traditional lenders work with crypto businesses. As wall street banks weigh ...
A DeFi incident has left Venus Protocol with roughly $2 million in bad debt after an attacker manipulated THE token p...
U.S. prosecutors in New York investigate links between Colombia's president and drug traffickers, while the DEA desig...